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Abstract 1 
 2 
Objective: The objective of this study was to assess and compare the features of the 3 bemfola vs. Gonal-f and Puregon injection pens. 4 
Methods: Females who intended to undergo hormonal treatment received the three 5 different pens in a randomised, consecutive sequence. For each of the pens, the 6 potential patients completed an Injection Pen Assessment Questionnaire (IPAQ), as 7 well as a questionnaire comparing the handling, convenience and preference among 8 the 3 pens.   9 
Results: The mean score on the visual analogue scale (VAS) for the bemfola pen was 10 77.8±14.0, followed by the Puregon pen (72.1±12.4) and the Gonal-f pen 11 (68.6±16.4). The bemfola pen was superior to both competitor devices in pen size, 12 inconspicuousness, ease of use, and dose changing; no significant differences to both 13 competitor pens were observed in the way the pen looks, the way the pen feels, and 14 the easiness to inject the volume. The “overall” assessment was significantly better 15 for the bemfola pen when compared to the Gonal-f pen (p=0.0019), while no 16 significant difference was observed between the bemfola and Puregon pens. 17 
Conclusions: This study demonstrated significantly higher ratings for pen size, 18 
inconspicuousness, ease of use and dose adjustment for the bemfola pen compared to 19 
other marketed pens.  20 
 21 
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  24 
Introduction 25  26 Follicle stimulating hormone (FSH) is a pituitary glycoprotein hormone that plays a 27 key role in regulating reproductive function in both males and females. 28 Recombinant human FSH (r-hFSH), such as Gonal-f and Puregon, have been in 29 widespead use since the 1990s1. Biosimilar versions of r-FSH have recently been 30 developed in order to provide economically attractive r-hFSH alternatives of high 31 quality. 32 Bemfola, a biosimilar r-hFSH, is delivered in a novel, innovative injector pen system 33 (reddot design award 2011). The bemfola pen is a single-use, disposable pen 34 available in 5 different dose strengths (i.e., 75IU, 150IU, 225IU, 300IU and 450IU). 35 The bemfola pen allow a fine-tuned dosing adjustment in 12.5IU and 25IU 36 increments. Other characteristics of the single-use pen are volume and injection-37 control mechanisms by visual aids such as coloured bars indicating the injection 38 volume. The clearly legible selected dose (as well as a click signal after successful 39 copmletion of the injection) avoid dosing errors, which in turn may improve therapy 40 compliance. If patients need a lower dose than the maximum ejection volume, an in-41 built lock prevents re-use of the pen device in order to reduce redosing for patient 42 safety. The remaining dose is discarded. 43 Non-compliance to hormonal treatment regimens represents a critical obstacle to 44 reaching therapeutic goals1-4. The use of pens by patients is often limited by factors 45 such as fear of injection, but correct use of the pen can be also related to the device 46 itself. Accordingly, easy-to-use devices may positively influence patient compliance. 47 
The convenient and simple handling of a pen would be expected to increase 48 adherence to the prescribed treatment regimen and therefore lead to a higher 49 success rate of hormonal treatment.  50 The objective of this study was to assess and compare the features of the bemfola vs. 51 Gonal-f and Puregon injection pens.  52 
 53 
Material and Methods 54  55 This investigation was conducted as a non-invasive survey and thus did not require 56 ethics approval. Two fertility centres, one each in Switzerland and the United 57 Kingdom, participated in this investigation. 58 
Study Population: The investigation was conducted in female subjects who 59 considered undergoing hormonal treatment for the first time. None of the study 60 subjects had ever previously used any pen medication delivery system. A total of 65 61 female subjects between 25 and 40 years of age participated in this study.  62 
Materials: The materials used were the bemfola pen (described in this section as BP; 63 Finox AG, Switzerland), Gonal-f pen (described in this section as GP; Merck Serono 64 AG, Switzerland and United Kingdom, and Puregon pen (described in this section as 65 PP; MSD Merck Sharp & Dohme AG, Switzerland). Each pen was provided as a part 66 of a training kit containing saline solution or water for injection but otherwise 67 identical to the commercial version.  68 
Study Design: Female patients who intended to undergo hormonal treatment 69 received the 3 pens in a randomised, consecutive sequence. Subjects completed an 70 
Injection Pen Assessment Questionnaire (IPAQ)6-7 and thereafter completed a 71 concluding questionnaire comparing the handling, convenience and preference 72 among the 3 pens. All data were collected anonymously. Six alternative sequences of 73 pens (BP-GP-PP / BP-PP-GP / GP-BP-PP / GP-PP-BP / PP-GP-BP / PP-BP-GP) were 74 possible and randomised according to a randomisation list. Consecutive User IDs 75 (01 to 36) indicated for each user a randomly assigned sequence. Users received the 76 3 pens one after the other in a randomly indicated sequence.   77 
Testing Procedure: Subjects were informed about this survey by the treating 78 physician or study nurse during regular visits at the fertility centre while discussing 79 an anticipated hormonal fertility treatment. Upon receiving the subject’s consent to 80 participate, the treating physician or the study nurse conducted the survey. Each 81 subject was instructed by the treating physician or the study nurse and tested 82 consecutively all 3 pens (cross-over design with random sequence). The treating 83 physician or the nurse explained how to use the first of the 3 pens (BP, GP or PP); 84 subjects were instructed to start with an intended administration of 225IU a day 85 followed by a dose increase to 300IU. The instruction included also the use of the 86 closing cap as well as disposing of the needle after injection. The subject then 87 independently completed the entire handling procedure (without help or support 88 from the study nurse or the treating physician) with the first pen. The pen contents 89 were injected into a demonstration cushion. Afterwards the subject’s responses 90 were recorded in the first questionnaire (Q1). This procedure was repeated exactly 91 the same way for the second and for the third pen, then completing the second 92 questionnaire (Q2) and the third questionnaire (Q3) respectively. After the 93 
evaluation of all 3 pens was finished, subjects were asked to complete a concluding 94 questionnaire (QEnd), comparing the handling, convenience and preference of all 95 the 3 pens.  96 
Assessments:  Information on baseline characteristics (i.e., age and confirmation that 97 potential patients had never previously used a pen delivery system for IVF 98 treatment) was collected from each subject. Questionnaire structure for each pen 99 (Q1, Q2, Q3) addressed appearance and perception (size, handling during injection, 100 overall opinion) as well as comparative preferences and convenience at the end 101 (QEnd). The following scores were used: 1=best pen, 2= second best pen, 3=last 102 choice). 103 
Statistical methods: Complete Case Record Forms (CRFs) consisting of Q1, Q2, Q3, 104 and QEnd were collected; single data entry was made on an Oracle database and 105 descriptive statistics were performed. The pre-defined objective for reported 106 features of pens defined a difference of 20±50 on the VAS score (0 to 100) as 107 significant when BP was compared with GP and PP, respectively. A sample size of 52 108 had an 80% power to detect a difference in means of 20 (e.g., a first-condition mean 109 [µ1] of 50 and a second-condition mean [µ2] of 30) assuming a standard deviation of 110 differences of 50 and using a paired t-test with a 0.050 2-sided significance level. In 111 order to compensate for potential drop-outs and invalid completion of CRFs, a 112 population of 60 users was considered to be sufficient. All users who completed 113 questionnaires for all 3 pens and the final assessments (Q1, Q2, Q3 and QEnd) were 114 included in the analysis. User-reported outcomes (VAS Scores) and ranking scores 115 were assessed using descriptive statistics. The T-test for quantitative data was used 116 
to analyse all VAS scores of all items for the 3 pens, while the preference ranking 117 score was assessed with a Wilcoxon signed-rank test for categorical data. 118   119 
Results 120  121 The highest numerical mean VAS scores were observed for the bemfola pen in 10 122 out of 11 items (table 1 and figure 1). As a consequence, the overall mean score of 123 the bemfola pen was the highest with 77.8±14.0 followed by the Puregon pen 124 (72.1±12.4) and the Gonal-f pen (68.6±16.4).  125 Statistical analysis revealed significantly higher VAS scores for the bemfola pen in 8 126 out of 11 items when compared to the Gonal-f pen, and in 4 out of 11 items when 127 compared to the Puregon pen. The bemfola pen was superior to both competitor 128 devices in pen size, inconspicuousness, ease of use, and dose changing; no 129 significant differences to either competitor pen were observed in the way the pen 130 looks, the way the pen feels, and the easiness to inject the pen volume (table 1). The 131 “Overall” assessment was significantly better for the bemfola pen when compared to 132 the Gonal-f pen (p=0.0019), while no significant difference was observed between 133 the bemfola and Puregon pen.  134 The bemfola pen showed the highest proportion of “best” choice in all 8 preference 135 
and convenience items (table 2 and figure 2). The total mean proportion of the “best” 136 ranking for the bemfola pen was 62% and markedly higher compared to the mean 137 proportion for the “best” ranking for the Puregon pen (26%) and the Gonal-f pen 138 (12%).  The proportion of “last” ranking was highest in 5 items (size, appearance, 139 holding, inconspicuousness, and injection performance) for the Gonal-f pen and in 2 140 items for the Puregon pen (learning of use and injection preparation) and similar for 141 
both pens, the Gonal-f pen and the Puregon pen,  with regards to injection handling 142 (handling after the injection).   143 Statistical analysis revealed significantly better rankings for the bemfola pen in 7 144 out of 8 items when compared to the Gonal-f pen, and in 4 out of 8 items when 145 compared to the Puregon pen (table 3). The bemfola pen showed a superior ranking 146 to both comparator pens for 4 items (pen size, learning of use, injection preparation, 147 and injection handling), while no significant difference to either comparator pen 148 was observed for one item (injection performance). 149  150  151  152  153  154   155 
Discussion 156  157 This study conducted in Swiss and British fertility centres included 65 female 158 subjects considering a therapy with FSH. In addition, this non-invasive study aimed 159 to analyse the appearance, perception and handling as well as the convenience and 160 preference of the bemfola pen and to compare these features and preferences with 161 the widely used Gonal-f and the Puregon pens. Results demonstrated significant 162 benefits and preferences for the bemfola pen compared to the Gonal-f and the 163 Puregon pen. Highest mean VAS scores in 10 of 11 features were observed for the 164 bemfola pen, which also had the highest proportion of “best” choice in all 8 items 165 assessing preference and convenience.   166 Outcomes on features and preferences of the 3 pens were consistent for the 167 majority of assessments. The bemfola pen showed higher VAS scores and clearly 168 better rankings for the pen size, the learning and facility in using the pen compared 169 to both Gonal-f and Puregon pens. The “inconspicuousness” of the bemfola pen was a 170 significantly better feature compared to both competitors and showed a 171 significantly higher preference when matched to the Gonal-f pen, while the 172 preference compared to the Puregon pen showed a positive trend in favour of the 173 bemfola® pen (p=0.0615). 174 The VAS scores of the bemfola pen on the appearance (“how the pen looks”) and feel 175 (“how the pen feels”) were similar when related to both challengers, while the 176 preference of the bemfola pen on appearance (“how the pen looks”) and handling 177 (“holding in your hands”) was significantly higher when compared to the Gonal-f 178 
pen. There were also features such as injecting the volume or the preference on 179 performing the injection which were comparable for all three pens, while the 180 preference for handling after the injection was rated significantly higher for the 181 bemfola pen compared to both the Gonal-f and Puregon pens.  182 The results showed also clearly that the bemfola pen was superior to the Gonal-f pen 183 with regards to the features on priming and overall use of the pen as well as the 184 setting and changing the doses. This is reflected by the significantly higher 185 preference for preparing the injection, while the ratings of these features were 186 similar between both bemfola and Puregon pens.  187 In conclusion, the results of this study demonstrated the benefits of the bemfola pen, 188 as well as the potential patients’ preference for the bemfola pen compared to 189 available alternatives. These differences were considerable when compared to the 190 Puregon pen and even more marked regarding the Gonal-f pen based on the 191 potential patients’ assessments. These findings suggest that the ease, look and 192 handling of the bemfola pen may potentially translate to increased patient 193 preference and compliance which requires additional study.  194   195 
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Table 1:  Mean (±SD) VAS Scores (0 to 100) and p-values of 11 items assessing the appearance, perception and handling of 
the bemfola, Gonal-f and the Puregon pens   232 
  bemfola Gonal-f Puregon bemfola vs. Gonal-f bemfola vs. Puregon 
 
Mean SD Mean SD Mean SD p-value p-value 
Appearance and perception 
      
  
Size of the pen 77.5 ±18.8 62.2 ±22.4 65.5 ±22.0 <0.0001 0.0016 
The way the pen look 65.0 ±23.0 59.6 ±23.5 65.7 ±22.5 n.s. n.s. 
The way the pen feels 71.8 ±20.4 65.4 ±22.5 67.5 ±17.7 n.s. n.s. 
The inconspicuousness of the pen 72.0 ±20.5 57.5 ±25.1 60.5 ±22.2 0.0006 0.0035 
How easy was it to learn how to use the pen 84.9 ±14.2 74.1 ±17.4 76.0 ±17.0 <0.0001 0.0009 
Handling of pen during injection         
Priming the pen 81.8 ±16.5 74.8 ±16.2 76.6 ±16.0 0.0004 n.s. 
Setting the dose 83.8 ±18.4 77.1 ±19.6 80.9 ±15.0 0.0238 n.s. 
Changing the dose 86.9 ±13.3 71.9 ±20.4 75.3 ±20.3 < 0.0001 < 0.0001 
Injecting the volume 74.1 ±23.4 71.4 ±24.9 72.6 ±21.9 n.s. n.s. 
Knowing when the injection pen has been 
completed 78.6 ±21.8 68.5 ±25.9 78.1 ±15.6 
 
0.0017 
 
n.s. 
Overall         
How easy was it overall to use the pen 79.7 ±18.2 72.4 ±18.1 74.8 ±17.0 0.0019 n.s. 
Total mean of scores 77.8 ±14.0 68.6 ±16.4 72.1 ±12.4   
 233  234 
Figure 1: Mean VAS Scores (0 to 100) of 11 items assessing the appearance, perception 235 
and handling of the bemfola, Gonal-f and the Puregon pens 236   237 
0 20 40 60 80 100Size of the pen
The way the pen look
The way the pen feels
The inconspicousness of the pen
How easy was it to learn how to use thepen
Priming the pen
Setting the dose
Changing the dose
Injecting the volume
Knowing when the injection pen has beencompleted
How easy was it overall to use the pen
Bemfola Gonal-f Puregon
Preference and convenience bemfola  Gonal-f Puregon 
 
Best  Second Last Best  Second Last Best  Second Last 
Size of the pen 75% 8% 17% 3% 51% 46% 22% 43% 35% 
The way the pen look like 46% 26% 28% 15% 46% 38% 38% 29% 32% 
Hold the pen in your hands 55% 15% 29% 11% 49% 40% 34% 37% 29% 
Inconspicuousness of the pen 65% 12% 23% 3% 55% 42% 32% 34% 34% 
Learning how to use the pen 69% 12% 18% 11% 54% 35% 18% 37% 45% 
Preparing the injection 74% 11% 15% 8% 60% 32% 17% 34% 49% 
Performing the injection 37% 25% 38% 31% 38% 31% 34% 38% 28% 
Handling after the injection 71% 14% 15% 12% 45% 43% 15% 42% 43% 
Total mean of ranking 62% 15% 23% 12% 50% 38% 26% 37% 37%  240 
Table 2:  Ranking (percent of best, second and last ranking) of 8 items assessing the preference 
and convenience of the bemfola, Gonal-f and the Puregon pens  241  242   243 
  
 
Figure 2: Ranking (percent of best, second and last choice) of 8 items assessing the 244 
preference and convenience of the bemfola, Gonal-f and the Puregon pens   245 
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Preference and convenience 
bemfola 
vs 
Gonal-f 
 
bemfola 
vs 
Puregon 
 
 p values p values 
The size of the pen < 0.0001 0.0004 
The way the pen look like 0.0183 n.s. 
To hold the pen in your hands 0.0010 n.s. 
The inconspicuousness of the pen < 0.0001 n.s. 
For learning on how to use the pen < 0.0001 < 0.0001 
For preparing the injection < 0.0001 < 0.0001 
For performing the injection n.s. n.s. 
For handling after the injection < 0.0001 < 0.0001 
 246 
Table 3:  Ranking (percent of best, second and last ranking) of 8 items assessing the preference 
and convenience of the bemfola, Gonal-f and the Puregon pens  247  248  249  250 
